How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS

Mischak, H. (2013) How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS. Proteomics Clinical Applications, 6(9-10), pp. 437-442. (doi: 10.1002/prca.201200027)

Full text not currently available from Enlighten.

Publisher's URL:


Clinical proteomics is defined as application of proteome analysis aiming at improving the current clinical situation. As such, the success of clinical proteomics should be assessed based on the clinical impact following implementation of the findings. While we have experienced significant technological advancements in mass spectrometry in the last years, based on the above measure, this has not at all resulted in similar advancements in clinical proteomics. Although a large number of proteomic biomarkers have been described, most of them were not subsequently validated, and certainly have had no impact in clinical decision making as yet. What is more, under the current conditions it appears likely that the situation will not change significantly: we will be flooded by reports on biomarkers, but not see any implementation. In this article some key issues in proteomic biomarker research are pinpointed, based on the experience with CE-MS, likely also holding true for biomarkers resulting from other analysis domains.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Mischak, Professor Harald
Authors: Mischak, H.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:Proteomics Clinical Applications
ISSN (Online):1862-8354
Related URLs:

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
546181Development of an efficient, robust MS-based platform for early detection of acute kidney injuryHarald MischakMedical Research Council (MRC)G1000791RI CARDIOVASCULAR & MEDICAL SCIENCES